James C Yang

List of Publications by Year
in descending order

70 papers	26,394 citations	70961 41 h-index	102304 66 g-index
70 all docs	70 docs citations	70 times ranked	19048 citing authors

#	Article	IF	Citations
1	A Randomized Trial of Bevacizumab, an Antiâ€"Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer. New England Journal of Medicine, 2003, 349, 427-434.	13.9	2,640
2	Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes. Science, 2006, 314, 126-129.	6.0	2,352
3	Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2. Molecular Therapy, 2010, 18, 843-851.	3.7	2,079
4	Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma. New England Journal of Medicine, 1988, 319, 1676-1680.	13.9	2,076
5	Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy. Clinical Cancer Research, 2011, 17, 4550-4557.	3.2	1,823
6	Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Medicine, 1998, 4, 321-327.	15.2	1,693
7	Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma. Journal of Clinical Oncology, 2005, 23, 2346-2357.	0.8	1,452
8	Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1. Journal of Clinical Oncology, 2011, 29, 917-924.	0.8	1,427
9	Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood, 2009, 114, 535-546.	0.6	1,280
10	Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens. Journal of Clinical Oncology, 2008, 26, 5233-5239.	0.8	1,210
11	PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. Journal of Clinical Investigation, 2014, 124, 2246-2259.	3.9	892
12	T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. Molecular Therapy, 2011, 19, 620-626.	3.7	857
13	Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nature Medicine, 2016, 22, 433-438.	15.2	721
14	A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1â€"Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response. Clinical Cancer Research, 2015, 21, 1019-1027.	3.2	677
15	Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis. Journal of Immunotherapy, 2007, 30, 825-830.	1.2	656
16	Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions. Clinical Cancer Research, 2014, 20, 3401-3410.	3.2	364
17	A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma. Journal of Immunotherapy, 2002, 25, 243-251.	1.2	326
18	Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma. Clinical Cancer Research, 2015, 21, 2278-2288.	3.2	310

#	Article	IF	Citations
19	Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2016, 34, 2389-2397.	0.8	293
20	Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor TÂCell Therapy. Molecular Therapy, 2017, 25, 2245-2253.	3.7	227
21	CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nature Communications, 2019, 10, 4016.	5.8	208
22	Localization of111Indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer, 1994, 73, 1731-1737.	2.0	204
23	Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncology, The, 2017, 18, 792-802.	5.1	203
24	In Vivo Distribution of Adoptively Transferred Indium- 111- Labeled Tumor Infiltrating Lymphocytes and Peripheral Blood Lymphocytes in Patients With Metastatic Melanoma. Journal of the National Cancer Institute, 1989, 81, 1709-1717.	3.0	176
25	Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors. Cancer Immunology Research, 2016, 4, 204-214.	1.6	175
26	Selection of CD8+PD-1+ Lymphocytes in Fresh Human Melanomas Enriches for Tumor-reactive T Cells. Journal of Immunotherapy, 2010, 33, 956-964.	1.2	174
27	Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science, 2022, 375, 877-884.	6.0	156
28	Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. Journal of Clinical Oncology, 2020, 38, 3805-3815.	0.8	129
29	Bevacizumab for Patients with Metastatic Renal Cancer: Fig. 1.. Clinical Cancer Research, 2004, 10, 6367S-6370S.	3.2	125
30	Landscape of Tumor Antigens in T Cell Immunotherapy. Journal of Immunology, 2015, 195, 5117-5122.	0.4	124
31	CD70, a novel target of CAR T-cell therapy for gliomas. Neuro-Oncology, 2018, 20, 55-65.	0.6	122
32	Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes. Journal of Clinical Investigation, 2019, 129, 4992-5004.	3.9	107
33	Immunotherapy for Renal Cell Cancer. Journal of Clinical Oncology, 2006, 24, 5576-5583.	0.8	105
34	Serum endostatin levels are elevated in patients with soft tissue sarcoma. Cancer, 2001, 91, 1525-1529.	2.0	90
35	The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. Cancer, 1995, 76, 687-694.	2.0	79
36	Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes. Journal of Clinical Oncology, 2022, 40, 1741-1754.	0.8	65

#	Article	IF	Citations
37	Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers. Clinical Cancer Research, 2017, 23, 2267-2276.	3.2	64
38	A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers. Cancer Cell, 2022, 40, 479-493.e6.	7.7	64
39	A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-Î³ chain chimeric receptor gene recognizing a human ovarian cancer antigen. Nature Medicine, 1998, 4, 168-172.	15.2	63
40	Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy. Cancer, 1992, 69, 1850-1855.	2.0	61
41	Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptorâ€"Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors. Cancer Immunology Research, 2022, 10, 932-946.	1.6	52
42	The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma. Cancer, 1995, 75, 1030-1037.	2.0	50
43	Persistence of CTL Clones Targeting Melanocyte Differentiation Antigens Was Insufficient to Mediate Significant Melanoma Regression in Humans. Clinical Cancer Research, 2015, 21, 534-543.	3.2	47
44	Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases. Journal of Immunotherapy, 2018, 41, 241-247.	1.2	40
45	Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma. Clinical Cancer Research, 2021, 27, 5289-5298.	3.2	39
46	Toxicities Associated With Adoptive T-Cell Transfer for Cancer. Cancer Journal (Sudbury, Mass), 2015, 21, 506-509.	1.0	38
47	Treatment of Oligometastases After Successful Immunotherapy. Seminars in Radiation Oncology, 2006, 16, 131-135.	1.0	28
48	Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma Patients. Annals of Surgical Oncology, 2017, 24, 947-951.	0.7	26
49	Mutated RAS: Targeting the â€œUntargetableâ€•with T Cells. Clinical Cancer Research, 2020, 26, 537-544.	3.2	25
50	Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma. Annals of Surgical Oncology, 2017, 24, 135-141.	0.7	24
51	Reply to "Cancer vaccines: pessimism in check". Nature Medicine, 2004, 10, 1279-1280.	15.2	19
52	Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma. Molecular and Cellular Proteomics, 2021, 20, 100136.	2.5	19
53	Genomic profiling of multiple sequentially acquired tumor metastatic sites from an â€œexceptional responderâ€•lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response. Journal of Physical Education and Sports Management, 2016, 2, a001263.	0.5	18
54	Neoantigen Identification and Response to Adoptive Cell Transfer in Antiâ€"PD-1 NaÃ¯ve and Experienced Patients with Metastatic Melanoma. Clinical Cancer Research, 2022, 28, 3042-3052.	3.2	18

#	Article	IF	Citations
55	Why is sentinel lymph node biopsy 'standard of care' for melanoma?. Nature Reviews Clinical Oncology, 2014, 11, 245-246.	12.5	16
56	Deep and Durable Remissions of Relapsed Multiple Myeloma on a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain. Blood, 2020, 136, 50-51.	0.6	14
57	Vitespen: a vaccine for renal cancer?. Lancet, The, 2008, 372, 92-93.	6.3	13
58	Adoptive cellular immunotherapy of cancer in mice using allogeneic T-cells. Annals of Surgical Oncology, 1996, 3, 67-73.	0.7	12
59	Melanoma Vaccines. Cancer Journal (Sudbury, Mass), 2011, 17, 277-282.	1.0	10
60	Adoptive T-Cell Therapy for Solid Malignancies. Surgical Oncology Clinics of North America, 2019, 28, 465-479.	0.6	10
61	Treatment of Patients with T Cells Expressing a Fully-Human Anti-BCMA CAR with a Heavy-Chain Antigen-Recognition Domain Caused High Rates of Sustained Complete Responses and Relatively Mild Toxicity. Blood, 2021, 138, 3837-3837.	0.6	8
62	Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center experience. Leukemia and Lymphoma, 2022, 63, 2469-2473.	0.6	6
63	The adoptive transfer of cultured T cells for patients with metastatic melanoma. Clinics in Dermatology, 2013, 31, 209-219.	0.8	5
64	Novel MHC-Independent Î±Î²TCRs Specific for CD48, CD102, and CD155 Self-Proteins and Their Selection in the Thymus. Frontiers in Immunology, 2020, 11, 1216.	2.2	3
65	The Immunotherapy Roadmap. Clinical Cancer Research, 2016, 22, 275-276.	3.2	2
66	MSLT-Iâ€"response of clinical trial investigators. Nature Reviews Clinical Oncology, 2014, 11, 680-680.	12.5	1
67	Localization of 111Indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. , 1994, 73, 1731.		1
68	The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. , 1995, 76, 687.		1
69	Debugging the Black Box. Cancer Discovery, 2017, 7, 250-251.	7.7	0
70	The ongoing mystery of renal cell cancer. Cell Reports Medicine, 2021, 2, 100445.	3.3	0